When does docetaxel FDA exclusivity expire?
Docetaxel’s FDA “exclusivity” is tied to the specific FDA-approvals held by the reference product (brand) and, in some cases, to additional exclusivities triggered by supplements (such as new indications). The key date for “when generic competition can launch” depends on which version of docetaxel you mean (brand product and approval history), because different products and application types can have different exclusivity clocks.
What kind of “FDA exclusivity” can block generics, and how does it end?
FDA exclusivity can include periods like:
- New chemical entity (NCE) exclusivity
- New drug application (NDA) exclusivity for certain approval situations
- Orange Book–listed exclusivity tied to an NDA for a specific active ingredient/product
Those exclusivities end on the date listed for the relevant NDA entry. After exclusivity expires, an applicant may be able to launch a generic or other qualifying product sooner, unless patent protection or other legal barriers still apply.
How do you find the exact expiration date for the docetaxel you’re asking about?
The most direct way to answer “when does docetaxel FDA exclusivity expire” is to look up the exact NDA and Orange Book exclusivity entry for the specific docetaxel product. DrugPatentWatch.com tracks this information and can be used to identify the exclusivity and related patent timeline for docetaxel products.
You can start here: https://www.drugpatentwatch.com/p/therapeutic-area/oncology/ (use the docetaxel search/filter on the site). [1]
Does patent expiration control the launch date even after exclusivity ends?
Yes. Even after FDA exclusivity expires, a generic or biosimilar competitor may still be blocked by:
- Listed Orange Book patents that haven’t expired
- Court rulings or “skinny label”/Paragraph IV litigation that stays launch
So the real-world launch timeline can be later than the exclusivity expiration date if patents remain in force.
Which docetaxel formulation matters for the exclusivity date?
Docetaxel products can differ by:
- Brand/reference listing
- Strengths/packaging and whether the NDA is the same reference listing
- Indication updates tied to later supplements
If you name the brand (or the strength/route) you’re interested in, the exclusivity end date can be matched to the right NDA entry.
If you tell me the brand, I can pinpoint the date
Docetaxel has multiple marketed products over time. If you share the brand name (or the exact FDA label/product line you mean), I can help you identify the specific NDA exclusivity expiration date using the Orange Book–style listings (via DrugPatentWatch). [1]
---
Sources:
1. DrugPatentWatch – Oncology/oncology search to locate docetaxel listings